AIM
PGNX

Acrospire Investment Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Acrospire Investment Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,014
Closed -$28K – 2702
2017
Q1 		$28K Sell
3,014
-27,499
-90% -$274K 0.02% 1413
2016
Q4 		$264K Buy
30,513
+22,713
+291% +$168K 0.11% 198
2016
Q3 		$49K Buy
+7,800
New +$47.2K 0.03% 1090

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Acrospire Investment Management's PGNX Position: Q2 2017 in Review

Acrospire Investment Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2017, closing a stake of 3,014 shares — an estimated $28K sold.

Acrospire Investment Management first reported a position in PGNX in Q3 2016 and held it in 3 quarters. The position peaked at $264K in Q4 2016. 152 funds tracked by Wall St. Rank hold PGNX as of Q2 2017.

  • Acrospire Investment Management reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 3,014 Progenics Pharmaceuticals Inc shares in Q2 2017, an estimated $28K.
  • Acrospire Investment Management first reported a position in Progenics Pharmaceuticals Inc in Q3 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Progenics Pharmaceuticals Inc position peaked at $264K in Q4 2016.
  • 152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.